NCT00257114View on ClinicalTrials.gov

Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability

PHASE4CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Primary Completion Date

March 31, 2007

Conditions
Multiple Myeloma
Interventions
DRUG

bortezomib

Trial Locations (1)

21215

Sinai Hospital of Baltimore, Baltimore

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT00257114 - Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability | Biotech Hunter | Biotech Hunter